Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Matsuo Y, Kamitani T.

PLoS One. 2010 May 5;5(5):e10481. doi: 10.1371/journal.pone.0010481.

PMID:
20463956
2.

Role of Ser129 phosphorylation of α-synuclein in melanoma cells.

Lee BR, Matsuo Y, Cashikar AG, Kamitani T.

J Cell Sci. 2013 Jan 15;126(Pt 2):696-704. doi: 10.1242/jcs.122093. Epub 2012 Nov 30.

PMID:
23203798
3.

Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.

Mehregan DR, Hamzavi I.

Am J Dermatopathol. 2000 Jun;22(3):247-50.

PMID:
10871068
4.

Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL.

Mod Pathol. 2008 Sep;21(9):1121-9. doi: 10.1038/modpathol.2008.100. Epub 2008 Jun 13.

PMID:
18552823
5.

Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.

Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M.

Cancer Res. 1989 Sep 15;49(18):5091-6.

PMID:
2548711
6.

Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN.

Cancer Res. 1997 Aug 1;57(15):3223-9.

PMID:
9242453
7.
8.

Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.

Björnhagen V, Bonfoco E, Brahme EM, Lindholm J, Auer G.

Am J Dermatopathol. 1994 Dec;16(6):615-23.

PMID:
7864299
9.

Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.

Busam KJ, Chen YT, Old LJ, Stockert E, Iversen K, Coplan KA, Rosai J, Barnhill RL, Jungbluth AA.

Am J Surg Pathol. 1998 Aug;22(8):976-82.

PMID:
9706977
10.

Proliferative activity of primary cutaneous melanocytic tumours.

Kuwata T, Kitagawa M, Kasuga T.

Virchows Arch A Pathol Anat Histopathol. 1993;423(5):359-64.

PMID:
7906909
11.

IMP-3 is a novel progression marker in malignant melanoma.

Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H.

Mod Pathol. 2008 Apr;21(4):431-7. doi: 10.1038/modpathol.3801016. Epub 2008 Jan 18.

PMID:
18204432
12.

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.

Boyd AS, Shakhtour B, Shyr Y.

J Am Acad Dermatol. 2008 May;58(5):750-4. doi: 10.1016/j.jaad.2007.12.026. Epub 2008 Feb 4.

PMID:
18249467
13.

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA.

BMC Cancer. 2012 Feb 22;12:73. doi: 10.1186/1471-2407-12-73.

PMID:
22356677
14.

Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.

Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, Garin-Chesa P.

J Invest Dermatol. 2003 Feb;120(2):182-8.

PMID:
12542520
15.

Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.

Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W.

Arch Dermatol Res. 1999 Feb-Mar;291(2-3):81-7.

PMID:
10195394
16.

Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.

Nazarian RM, Prieto VG, Elder DE, Duncan LM.

J Cutan Pathol. 2010 Apr;37 Suppl 1:41-7. doi: 10.1111/j.1600-0560.2010.01505.x.

PMID:
20482674
17.

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.

Brain. 2005 Nov;128(Pt 11):2654-64. Epub 2005 Jul 6.

PMID:
16000336
18.

p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.

Sparrow LE, Eldon MJ, English DR, Heenan PJ.

Am J Dermatopathol. 1998 Jun;20(3):255-61.

PMID:
9650698
19.

WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.

Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ.

Arch Ophthalmol. 2009 Aug;127(8):964-9. doi: 10.1001/archophthalmol.2009.183.

PMID:
19667332
20.

Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.

Holt JB, Sangueza OP, Levine EA, Shen P, Bergman S, Geisinger KR, Creager AJ.

Am J Clin Pathol. 2004 Jan;121(1):58-63.

PMID:
14750241

Supplemental Content

Support Center